Xu Yuyang, Li Keli, Li Yan, Li Yuan, Zhang Lina, Fan Chunxiang, Ren Minrui, Yin Zundong
Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou City, Zhejiang Province, China.
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
China CDC Wkly. 2024 Dec 13;6(50):1325-1330. doi: 10.46234/ccdcw2024.263.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: From 2010 to 2012, the incidence of adverse vaccine reactions from meningococcal vaccine (MenV) in China ranged from 8.46 to 56.30 per 100,000 doses.
WHAT IS ADDED BY THIS REPORT?: From 2013 to 2021, the overall reported rate of adverse events following immunization (AEFI) of five types of market-authorized MenV-containing vaccines in China was 37.87 per 100,000 doses administered, with a reported incidence of adverse vaccine reactions of 37.39 per 100,000 doses. The reported incidence of adverse vaccine reactions was comparable to that from 2010 to 2012 and perceived to be within an acceptable range. Most rare vaccine reactions were allergic rashes, and most of these cases were transient and non-serious.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: In China, the incidence of AEFI was very low, and serious abnormal reactions were extremely rare. We should continue to carry out technical training for vaccinators and on-site treatment capabilities to improve emergency treatment for anaphylactic shock and other serious events and ensure the continued safety of vaccination.
关于该主题已知的信息有哪些？：2010年至2012年，中国脑膜炎球菌疫苗（MenV）的不良疫苗反应发生率为每10万剂8.46至56.30例。
本报告新增了哪些内容？：2013年至2021年，中国五种市场授权的含脑膜炎球菌疫苗免疫接种后不良事件（AEFI）的总体报告率为每10万剂接种量37.87例，不良疫苗反应报告发生率为每10万剂37.39例。不良疫苗反应报告发生率与2010年至2012年相当，且被认为在可接受范围内。大多数罕见疫苗反应为过敏性皮疹，且大多数病例为短暂性且不严重。
对公共卫生实践有何启示？：在中国，AEFI发生率非常低，严重异常反应极为罕见。我们应继续开展针对疫苗接种人员的技术培训和现场处理能力培训，以改善对过敏性休克等严重事件的应急处理，并确保疫苗接种的持续安全性。
